{"parse":{"title":"Patient Reported Outcome Indices for Multiple Sclerosis","pageid":40738710,"revid":830355558,"text":{"*":"<div class=\"mw-parser-output\"><p>The <b>Patient Reported Outcome Indices for Multiple Sclerosis</b> (PRIMUS) is a disease specific <a href=\"/wiki/Patient-reported_outcome\" title=\"Patient-reported outcome\">patient-reported outcome</a> <a href=\"/wiki/Questionnaire\" title=\"Questionnaire\">questionnaire</a> which measures the <a href=\"/wiki/Quality_of_life\" title=\"Quality of life\">quality of life</a> (QoL) of patients suffering from <a href=\"/wiki/Multiple_sclerosis\" title=\"Multiple sclerosis\">multiple sclerosis</a>.<sup id=\"cite_ref-mckenna_1-0\" class=\"reference\"><a href=\"#cite_note-mckenna-1\">&#91;1&#93;</a></sup>\n</p><p>The measure contains an assessment of quality of life, activity limitations and symptoms. A higher score on any or all of these scales indicates a lower quality of life due to the disease.<sup id=\"cite_ref-twiss_2-0\" class=\"reference\"><a href=\"#cite_note-twiss-2\">&#91;2&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#History_and_properties\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">History and properties</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#International_use\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">International use</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Clinical_studies\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Clinical studies</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"History_and_properties\">History and properties</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis&amp;action=edit&amp;section=1\" title=\"Edit section: History and properties\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>First published in 2009 by Galen Research and funded by <a href=\"/wiki/Novartis_Pharmaceuticals\" class=\"mw-redirect\" title=\"Novartis Pharmaceuticals\">Novartis Pharmaceuticals</a>, the PRIMUS was developed in order to provide a more holistic view of the impact of MS on a patient.<sup id=\"cite_ref-mckenna_1-1\" class=\"reference\"><a href=\"#cite_note-mckenna-1\">&#91;1&#93;</a></sup>\n</p><p>The measure has three scales: quality of life, symptoms and activity limitations, which are designed to be used together or as standalone measures.<sup id=\"cite_ref-twiss_2-1\" class=\"reference\"><a href=\"#cite_note-twiss-2\">&#91;2&#93;</a></sup> The QoL and symptom scales are based on simple statements with <a href=\"/wiki/Dichotomous_question\" class=\"mw-redirect\" title=\"Dichotomous question\">dichotomous</a> response options.  Each scale has a total score which ranges from 0 to 22. The activity scale is based on 15 statements describing tasks. Patients are asked to rate their ability to perform these tasks on a scale from 1 to 3. The total score of the activities section ranges from 0 to 30.<sup id=\"cite_ref-2kenna_3-0\" class=\"reference\"><a href=\"#cite_note-2kenna-3\">&#91;3&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"International_use\">International use</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis&amp;action=edit&amp;section=2\" title=\"Edit section: International use\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Since the development of the PRIMUS, it has been translated into several languages including Canadian English and French, French, German, Italian, Spanish, Swedish, US English,<sup id=\"cite_ref-2kenna_3-1\" class=\"reference\"><a href=\"#cite_note-2kenna-3\">&#91;3&#93;</a></sup> Australian and New Zealand English and US Spanish.<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup> This has allowed researchers to conduct studies for specific populations, such as Spain<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup> and Europe.<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Clinical_studies\">Clinical studies</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis&amp;action=edit&amp;section=3\" title=\"Edit section: Clinical studies\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The PRIMUS has been utilized in clinical trials which assess the efficacy of a treatment or medication. If a patient\u2019s score on the PRIMUS changes after a trial has taken place, it is inferred that the trial has had an effect on the patient\u2019s quality of life. PRIMUS has been used to assess the efficacy of <a href=\"/wiki/Fingolimod\" title=\"Fingolimod\">fingolimod</a><sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup> and <a href=\"/wiki/Rivastigmine\" title=\"Rivastigmine\">rivastigmine</a>.<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis&amp;action=edit&amp;section=4\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-mckenna-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-mckenna_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-mckenna_1-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Doward, LC; McKenna, S.P.; Meads, D.M.; Twiss, J; Eckert, BJ (2009). <a rel=\"nofollow\" class=\"external text\" href=\"http://msj.sagepub.com/content/15/9/1092.abstract\">\"The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)\"</a>. <i>Multiple Sclerosis Journal</i>. <b>15</b> (9): 1092\u20131102. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1177/1352458509106513\">10.1177/1352458509106513</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19556315\">19556315</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Multiple+Sclerosis+Journal&amp;rft.atitle=The+development+of+patient-reported+outcome+indices+for+multiple+sclerosis+%28PRIMUS%29&amp;rft.volume=15&amp;rft.issue=9&amp;rft.pages=1092-1102&amp;rft.date=2009&amp;rft_id=info%3Adoi%2F10.1177%2F1352458509106513&amp;rft_id=info%3Apmid%2F19556315&amp;rft.aulast=Doward&amp;rft.aufirst=LC&amp;rft.au=McKenna%2C+S.P.&amp;rft.au=Meads%2C+D.M.&amp;rft.au=Twiss%2C+J&amp;rft.au=Eckert%2C+BJ&amp;rft_id=http%3A%2F%2Fmsj.sagepub.com%2Fcontent%2F15%2F9%2F1092.abstract&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-twiss-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-twiss_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-twiss_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Twiss, James; Doward, Lynda C.; McKenna, Stephen P.; Eckert, Benjamin (11/10/2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.hqlo.com/content/8/1/117\">\"Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS)\"</a>. <i>Health And Quality Of Life Outcomes</i>. <b>8</b> (117): 1\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1186/1477-7525-8-117\">10.1186/1477-7525-8-117</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+And+Quality+Of+Life+Outcomes&amp;rft.atitle=Interpreting+scores+on+multiple+sclerosis-specific+patient+reported+outcome+measures+%28the+PRIMUS+and+U-FIS%29&amp;rft.chron=11%2F10%2F2010&amp;rft.volume=8&amp;rft.issue=117&amp;rft.pages=1-8&amp;rft_id=info%3Adoi%2F10.1186%2F1477-7525-8-117&amp;rft.aulast=Twiss&amp;rft.aufirst=James&amp;rft.au=Doward%2C+Lynda+C.&amp;rft.au=McKenna%2C+Stephen+P.&amp;rft.au=Eckert%2C+Benjamin&amp;rft_id=http%3A%2F%2Fwww.hqlo.com%2Fcontent%2F8%2F1%2F117&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <span style=\"font-size:100%\" class=\"error citation-comment\">Check date values in: <code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;date=</code> (<a href=\"/wiki/Help:CS1_errors#bad_date\" title=\"Help:CS1 errors\">help</a>)</span></span>\n</li>\n<li id=\"cite_note-2kenna-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-2kenna_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-2kenna_3-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">McKenna, Stephen P.; Doward, Lynda C.; Twiss, James; Hagell, Peter; Oprandi, Nadia C.; Fisk, John; Grand'Maison, Francois; Bhan, Virender; Arbizu, Txomin; Brassat, David; Kohlmann, Thomas; Meads, David M.; Eckert, Benjamin J. (December 2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4733.2010.00767.x/abstract\">\"International Development of the Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS)\"</a>. <i>Value in Health</i>. <b>13</b> (8): 946\u2013951. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/j.1524-4733.2010.00767.x\">10.1111/j.1524-4733.2010.00767.x</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Value+in+Health&amp;rft.atitle=International+Development+of+the+Patient-Reported+Outcome+Indices+for+Multiple+Sclerosis+%28PRIMUS%29&amp;rft.volume=13&amp;rft.issue=8&amp;rft.pages=946-951&amp;rft.date=2010-12&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1524-4733.2010.00767.x&amp;rft.aulast=McKenna&amp;rft.aufirst=Stephen+P.&amp;rft.au=Doward%2C+Lynda+C.&amp;rft.au=Twiss%2C+James&amp;rft.au=Hagell%2C+Peter&amp;rft.au=Oprandi%2C+Nadia+C.&amp;rft.au=Fisk%2C+John&amp;rft.au=Grand%27Maison%2C+Francois&amp;rft.au=Bhan%2C+Virender&amp;rft.au=Arbizu%2C+Txomin&amp;rft.au=Brassat%2C+David&amp;rft.au=Kohlmann%2C+Thomas&amp;rft.au=Meads%2C+David+M.&amp;rft.au=Eckert%2C+Benjamin+J.&amp;rft_id=http%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fj.1524-4733.2010.00767.x%2Fabstract&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.galen-research.com/measures-database/\">\"Measures Database\"</a>. <i>Galen-Research.com</i>. Galen Research<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Galen-Research.com&amp;rft.atitle=Measures+Database&amp;rft_id=http%3A%2F%2Fwww.galen-research.com%2Fmeasures-database%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hernandez, M.A.; Mora, S. (2013). <a rel=\"nofollow\" class=\"external text\" href=\"http://zl.elsevier.es/en/revista/neurologia-495/articulo/use-of-the-primus-scale-90217987\">\"Use of the PRIMUS scale to assess quality of life in a Spanish population of multiple sclerosis patients\"</a>. <i>Neurologia</i>. <b>28</b> (6): 340\u2013347. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.nrleng.2012.06.003\">10.1016/j.nrleng.2012.06.003</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurologia&amp;rft.atitle=Use+of+the+PRIMUS+scale+to+assess+quality+of+life+in+a+Spanish+population+of+multiple+sclerosis+patients.&amp;rft.volume=28&amp;rft.issue=6&amp;rft.pages=340-347&amp;rft.date=2013&amp;rft_id=info%3Adoi%2F10.1016%2Fj.nrleng.2012.06.003&amp;rft.aulast=Hernandez&amp;rft.aufirst=M.A.&amp;rft.au=Mora%2C+S.&amp;rft_id=http%3A%2F%2Fzl.elsevier.es%2Fen%2Frevista%2Fneurologia-495%2Farticulo%2Fuse-of-the-primus-scale-90217987&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Karampampa, Korinna; Gustavsson, Anders; Miltenburger, Carolin; Eckert, Benjamin (2012). <a rel=\"nofollow\" class=\"external text\" href=\"http://msj.sagepub.com/content/18/2_suppl/7\">\"Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries\"</a>. <i>Multiple Sclerosis</i>. <b>18</b> (2): 7\u201315. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1177/1352458512441566\">10.1177/1352458512441566</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">8 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Multiple+Sclerosis&amp;rft.atitle=Treatment+experience%2C+burden+and+unmet+needs+%28TRIBUNE%29+in+MS+study%3A+results+from+five+European+countries&amp;rft.volume=18&amp;rft.issue=2&amp;rft.pages=7-15&amp;rft.date=2012&amp;rft_id=info%3Adoi%2F10.1177%2F1352458512441566&amp;rft.aulast=Karampampa&amp;rft.aufirst=Korinna&amp;rft.au=Gustavsson%2C+Anders&amp;rft.au=Miltenburger%2C+Carolin&amp;rft.au=Eckert%2C+Benjamin&amp;rft_id=http%3A%2F%2Fmsj.sagepub.com%2Fcontent%2F18%2F2_suppl%2F7&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ziemssen, T.; Meergans, M.; Vollmar, P.; Kempcke, R; Tracik, F.; van Lokven, T. (October 2012). <a rel=\"nofollow\" class=\"external text\" href=\"http://msj.sagepub.com/content/18/4_suppl/55.extract\">\"Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya\u00ae) in multiple sclerosis patients in Germany (PANGAEA)\"</a>. <i>Multiple Sclerosis</i>. <b>18</b> (4): 222. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1177/1352458512459019\">10.1177/1352458512459019</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">9 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Multiple+Sclerosis&amp;rft.atitle=Study+design+and+first+interim+results+of+a+registry+study+to+establish+long-term+safety+and+pharmaco-economic+data+on+fingolimod+%28Gilenya%C2%AE%29+in+multiple+sclerosis+patients+in+Germany+%28PANGAEA%29&amp;rft.volume=18&amp;rft.issue=4&amp;rft.pages=222&amp;rft.date=2012-10&amp;rft_id=info%3Adoi%2F10.1177%2F1352458512459019&amp;rft.aulast=Ziemssen&amp;rft.aufirst=T.&amp;rft.au=Meergans%2C+M.&amp;rft.au=Vollmar%2C+P.&amp;rft.au=Kempcke%2C+R&amp;rft.au=Tracik%2C+F.&amp;rft.au=van+Lokven%2C+T.&amp;rft_id=http%3A%2F%2Fmsj.sagepub.com%2Fcontent%2F18%2F4_suppl%2F55.extract&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation conference\">T., van Lokven; Kempcke, R.; Ziemssen, T.; Meergans, M. (2011-10-20). <a rel=\"nofollow\" class=\"external text\" href=\"https://archive.is/20131108154143/http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=137571&amp;XNSPRACHE_ID=2&amp;XNKONGRESS_ID=150&amp;XNMASKEN_ID=900\">\"Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya\u00ae) in multiple sclerosis patients (PANGAEA)\"</a>. <i>5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis</i>. Amsterdam, The Netherlands. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=137571&amp;XNSPRACHE_ID=2&amp;XNKONGRESS_ID=150&amp;XNMASKEN_ID=900\">the original</a> on 2013-11-08<span class=\"reference-accessdate\">. Retrieved 09/10/2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=conference&amp;rft.atitle=Study+design+of+a+non-interventional+registry+study+to+establish+long-term+safety+and+pharmaco-economic+data+on+fingolimod+%28Gilenya%C2%AE%29+in+multiple+sclerosis+patients+%28PANGAEA%29&amp;rft.btitle=5th+Joint+triennial+congress+of+the+European+and+Americas+Committees+for+Treatment+and+Research+in+Multiple+Sclerosis&amp;rft.place=Amsterdam%2C+The+Netherlands&amp;rft.date=2011-10-20&amp;rft.aulast=T.&amp;rft.aufirst=van+Lokven&amp;rft.au=Kempcke%2C+R.&amp;rft.au=Ziemssen%2C+T.&amp;rft.au=Meergans%2C+M.&amp;rft_id=http%3A%2F%2Fregistration.akm.ch%2Feinsicht.php%3FXNABSTRACT_ID%3D137571%26XNSPRACHE_ID%3D2%26XNKONGRESS_ID%3D150%26XNMASKEN_ID%3D900&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <span style=\"font-size:100%\" class=\"error citation-comment\">Check date values in: <code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;accessdate=</code> (<a href=\"/wiki/Help:CS1_errors#bad_date\" title=\"Help:CS1 errors\">help</a>)</span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cascione, Mark; Wynn, Daniel; Agashivala, Neetu; McCague, Kevin; Pestreich, Linda; Schofield, Lesley; Kim, Edward; Barbato, Luigi (12/02/2013). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.neurology.org/cgi/content/meeting_abstract/80/1_MeetingAbstracts/P03.222\">\"Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod\"</a>. <i>Neurology</i>. <b>80</b> (1)<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">9 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Neurology&amp;rft.atitle=Patient-Reported+Treatment+Satisfaction%2C+Reasons+for+Therapy+Change%2C+and+Health-Related+Quality+of+Life+at+Baseline+from+the+Trial+To+Evaluate+Patient+OutComes%2C+Safety+and+Tolerability+of+Fingolimod&amp;rft.chron=12%2F02%2F2013&amp;rft.volume=80&amp;rft.issue=1&amp;rft.aulast=Cascione&amp;rft.aufirst=Mark&amp;rft.au=Wynn%2C+Daniel&amp;rft.au=Agashivala%2C+Neetu&amp;rft.au=McCague%2C+Kevin&amp;rft.au=Pestreich%2C+Linda&amp;rft.au=Schofield%2C+Lesley&amp;rft.au=Kim%2C+Edward&amp;rft.au=Barbato%2C+Luigi&amp;rft_id=http%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fmeeting_abstract%2F80%2F1_MeetingAbstracts%2FP03.222&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <span style=\"font-size:100%\" class=\"error citation-comment\">Check date values in: <code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;date=</code> (<a href=\"/wiki/Help:CS1_errors#bad_date\" title=\"Help:CS1 errors\">help</a>)</span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Maurer, M; Ortler, S; Baier, M; Meergans, M; Scherer, P; Hofmann, WE; Tracik, F. (2012-10-15). <a rel=\"nofollow\" class=\"external text\" href=\"http://msj.sagepub.com/content/19/5/631.abstract\">\"Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients\"</a>. <i>Multiple Sclerosis</i>. <b>19</b> (5): 631\u2013638. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1177/1352458512463481\">10.1177/1352458512463481</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23069874\">23069874</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">9 October</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Multiple+Sclerosis&amp;rft.atitle=Randomised+multicentre+trial+on+safety+and+efficacy+of+rivastigmine+in+cognitively+impaired+multiple+sclerosis+patients&amp;rft.volume=19&amp;rft.issue=5&amp;rft.pages=631-638&amp;rft.date=2012-10-15&amp;rft_id=info%3Adoi%2F10.1177%2F1352458512463481&amp;rft_id=info%3Apmid%2F23069874&amp;rft.aulast=Maurer&amp;rft.aufirst=M&amp;rft.au=Ortler%2C+S&amp;rft.au=Baier%2C+M&amp;rft.au=Meergans%2C+M&amp;rft.au=Scherer%2C+P&amp;rft.au=Hofmann%2C+WE&amp;rft.au=Tracik%2C+F.&amp;rft_id=http%3A%2F%2Fmsj.sagepub.com%2Fcontent%2F19%2F5%2F631.abstract&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APatient+Reported+Outcome+Indices+for+Multiple+Sclerosis\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw1271\nCached time: 20180909025856\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.156 seconds\nReal time usage: 0.176 seconds\nPreprocessor visited node count: 613/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 28437/2097152 bytes\nTemplate argument size: 119/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 18332/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.078/10.000 seconds\nLua memory usage: 3.01 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  140.080      1 Template:Reflist\n100.00%  140.080      1 -total\n 71.40%  100.013      8 Template:Cite_journal\n  4.98%    6.978      1 Template:Cite_conference\n  4.16%    5.827      1 Template:Cite_web\n  1.89%    2.649      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:40738710-0!canonical and timestamp 20180909025856 and revision id 830355558\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"CS1_errors:_dates"},{"sortkey":"","*":"Multiple_sclerosis"},{"sortkey":"","*":"Quality_of_life"},{"sortkey":"","*":"2009_introductions"}],"links":[{"ns":0,"exists":"","*":"Dichotomous question"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Fingolimod"},{"ns":0,"exists":"","*":"Multiple sclerosis"},{"ns":0,"exists":"","*":"Novartis Pharmaceuticals"},{"ns":0,"exists":"","*":"Patient-reported outcome"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Quality of life"},{"ns":0,"exists":"","*":"Questionnaire"},{"ns":0,"exists":"","*":"Rivastigmine"},{"ns":12,"exists":"","*":"Help:CS1 errors"}],"templates":[{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite conference"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":[],"externallinks":["http://msj.sagepub.com/content/15/9/1092.abstract","//doi.org/10.1177/1352458509106513","//www.ncbi.nlm.nih.gov/pubmed/19556315","http://www.hqlo.com/content/8/1/117","//doi.org/10.1186/1477-7525-8-117","http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4733.2010.00767.x/abstract","//doi.org/10.1111/j.1524-4733.2010.00767.x","http://www.galen-research.com/measures-database/","http://zl.elsevier.es/en/revista/neurologia-495/articulo/use-of-the-primus-scale-90217987","//doi.org/10.1016/j.nrleng.2012.06.003","http://msj.sagepub.com/content/18/2_suppl/7","//doi.org/10.1177/1352458512441566","http://msj.sagepub.com/content/18/4_suppl/55.extract","//doi.org/10.1177/1352458512459019","https://archive.is/20131108154143/http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=137571&XNSPRACHE_ID=2&XNKONGRESS_ID=150&XNMASKEN_ID=900","http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=137571&XNSPRACHE_ID=2&XNKONGRESS_ID=150&XNMASKEN_ID=900","http://www.neurology.org/cgi/content/meeting_abstract/80/1_MeetingAbstracts/P03.222","http://msj.sagepub.com/content/19/5/631.abstract","//doi.org/10.1177/1352458512463481","//www.ncbi.nlm.nih.gov/pubmed/23069874"],"sections":[{"toclevel":1,"level":"2","line":"History and properties","number":"1","index":"1","fromtitle":"Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis","byteoffset":1311,"anchor":"History_and_properties"},{"toclevel":1,"level":"2","line":"International use","number":"2","index":"2","fromtitle":"Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis","byteoffset":2808,"anchor":"International_use"},{"toclevel":1,"level":"2","line":"Clinical studies","number":"3","index":"3","fromtitle":"Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis","byteoffset":4176,"anchor":"Clinical_studies"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"4","fromtitle":"Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis","byteoffset":7105,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Patient Reported Outcome Indices for Multiple Sclerosis","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q17074249"}]}}